Alnylam Pharmaceuticals Inc. (ALNY)
ALNY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/0001628280-26-007497-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ALNY on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2004 |
| SEC CIK | 0001178670 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.7B |
| Net income | $313.7M |
| Operating income | $501.6M |
| Net margin | 8.4% |
| Operating margin | 13.5% |
| Revenue growth | +65.2% |
| Cash | $1.7B |
| Total assets | $5.0B |
| P/E (computed) | 68.2× |
| P/S (computed) | 5.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $1.8B cash; operating cash flow $245.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 133,937,576 (2026-10-23); 132,113,818 a year earlier; 125,492,927 three years earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-02-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $50.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.5B | $2.2B | $341.0M | $1.8B | $1.0B | Needs four quarters | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $1.3B | $164.5M | Not filed | $1.7B | $1.0B | Needs four quarters | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | Not filed | $206.0M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-10-29 |
| Q4 2025 2025-12-31 | $1.1B | $111.5M | $217.7M | $1.7B | $1.0B | $3.7B | 10-K 2026-02-12 |
| Q3 2025 2025-09-30 | $1.2B | $292.7M | $296.9M | $1.5B | $1.0B | $3.2B | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $773.7M | -$72.2M | $127.8M | $1.1B | $1.0B | $2.5B | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $594.2M | -$18.3M | -$118.3M | $1.0B | $1.0B | $2.3B | 10-Q 2025-05-01 |
| Q4 2024 2024-12-31 | $593.2M | -$83.8M | -$94.7M | $966.4M | $1.0B | $2.2B | 10-K 2026-02-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2020-06-05 |
| Latest annual report | 10-K | 2026-02-12 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-06 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.8% |
| 1 month | -26.3% |
| 3 months | -27.3% |
| Year to date | -58.5% |
| 1 year | -63.6% |
| From 52-week high | -65.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VTRS | Viatris Inc. | $20.74 | -0.38% | $23.8B |
| UTHR | United Therapeutics Corporation | $587.88 | -0.56% | $25.0B |
| ASND | Ascendis Pharma A/S Ordinary Share | $271.73 | -1.33% | $17.9B |
| INSM | Insmed Incorporated | $122.88 | +1.42% | $27.0B |
| ROIV | Roivant Sciences Ltd. Common Shares | $38.61 | -2.33% | $28.0B |
| JAZZ | Jazz Pharmaceuticals plc Common Stock (Ireland) | $239.77 | -0.74% | $15.4B |
| BBIO | BridgeBio Pharma Inc. | $77.36 | -1.20% | $15.1B |
| GMAB | Genmab A/S ADS | $51.57 | +0.39% | $32.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier